Users Online: 675
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

THE GREAT DEBATE: FOR IMATINIB AS THE FIRST LINE TKI CHOICE FOR CML

Is imatinib still the best choice as first-line oral TKI

Bansal Shweta

Year : 2014| Volume: 3| Issue : 1 | Page no: 83-86

   This article has been cited by
 
1 Observation of Imatinib and Nilotinib in the Treatment of Chronic Myeloid Leukemia
?? ?
World Journal of Cancer Research. 2019; 09(02): 69
[Pubmed]  [Google Scholar] [DOI]
2 Up regulation of KAI1 gene expression and apoptosis effect of imatinib mesylate in gastric adenocarcinoma (AGS) cell line
Seyed Ataollah Sadat Shandiz,Soheila Farasati,Banafshe Saeedi,Fahimeh Baghbani-Arani,Elham Akbari Asl,Behta Keshavarz-Pakseresht,Arian Rahimi,Artin Assadi,Hassan Noorbazargan,Maryam Rahimpour Hesari,Amir Mirzaie
Asian Pacific Journal of Tropical Disease. 2016; 6(2): 120
[Pubmed]  [Google Scholar] [DOI]
3 Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells
Sarbari Acharya,Sanjeeb K. Sahoo
Journal of Colloid and Interface Science. 2016; 467: 180
[Pubmed]  [Google Scholar] [DOI]
4 Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR
Seyed Ataollah Sadat Shandiz,Marjan Khosravani,Sepideh Mohammadi,Hassan Noorbazargan,Amir Mirzaie,Davoud Nouri Inanlou,Mojgan Dalirsaber Jalali,Hamidreza Jouzaghkar,Fahimeh Baghbani-Arani,Behta Keshavarz-Pakseresht
Asian Pacific Journal of Tropical Biomedicine. 2016; 6(2): 159
[Pubmed]  [Google Scholar] [DOI]
5 using 2 nd generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia
jayakar, v.
south asian journal of cancer. 2014; 3(1): 87-89
[Pubmed]  [Google Scholar]

 

Read this article